论文部分内容阅读
为了观察大剂量足叶乙甙(VP16)和粒细胞集落刺激因子(G-CSF)在恶性血液病人动员采集自体外周血造血干/祖细胞的有效性和安全性,对10例恶性血液病患者(多发性骨髓瘤6例,非霍奇金淋巴瘤4例),第1天用足叶乙甙1.6g/m2静脉持续滴注10小时,第3天起给予G-CSF5μg/kg,每日1次,皮下注射,直至采集结束。结果显示:用VP16后平均第11(9-13)天开始外周血造血干/祖细胞单采,获CD34+细胞9.4×106/kg(4.2-17.3×106/kg),每例CD34+细胞>4.0×106/kg。平均采集次数2.6(1-4)次。1例发生口咽黏膜炎、2例尿道炎、咽喉炎。结论:足叶乙甙1.6g/m2和G-CSF5μg/kg是恶性血液病动员采集自体干祖细胞的有效安全方案。
In order to observe the efficacy and safety of high-dose etoposide (VP16) and granulocyte-colony stimulating factor (G-CSF) mobilizing peripheral blood hematopoietic stem / progenitor cells collected from patients with malignant blood, 10 cases of hematological malignancies (6 cases of multiple myeloma, 4 cases of non-Hodgkin’s lymphoma). The first day of intravenous infusion of etoposide 1.6g / m2 continuous infusion of 10 hours, from the third day G-CSF given 5μg / kg, daily 1 times, subcutaneous injection, until the end of the acquisition. The results showed that peripheral blood hematopoietic stem / progenitor cells (PBMCs) were collected from mice with 9.4 × 106 / kg (4.2-17.3 × 106 / kg) of CD34 + cells and 4.0 × 106 / kg. The average number of acquisition 2.6 (1-4) times. One case had oropharyngeal mucositis, two cases of urethritis and pharyngitis. CONCLUSION: Etoposide 1.6g / m2 and G-CSF5μg / kg are effective safety regimens for collecting autologous stem and progenitor cells from patients with hematologic malignancies.